Cirius Therapeutics, Breakthrough T1D, And UVA Health Collaborate On Phase 2 Study Of MPC Inhibitor CIR-0602K In Type 1 Diabetes

RefinitivMoins d'1 minute de lecture

Cirius Therapeutics Inc (CSTX.O):

CIRIUS THERAPEUTICS, BREAKTHROUGH T1D, AND UVA HEALTH COLLABORATE ON PHASE 2 STUDY OF MPC INHIBITOR CIR-0602K IN TYPE 1 DIABETES

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles